
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
| Revenue (TTM) | $2.78B |
| Gross Profit (TTM) | $2.01B |
| EBITDA | $611.20M |
| Operating Margin | 20.80% |
| Return on Equity | 162.10% |
| Return on Assets | 20.10% |
| Revenue/Share (TTM) | $98.47 |
| Book Value | $15.54 |
| Price-to-Book | 37.19 |
| Price-to-Sales (TTM) | 5.80 |
| EV/Revenue | 5.66 |
| EV/EBITDA | 25.77 |
| Quarterly Earnings Growth (YoY) | 37.10% |
| Quarterly Revenue Growth (YoY) | 17.20% |
| Shares Outstanding | $27.91M |
| Float | $22.38M |
| % Insiders | 19.75% |
| % Institutions | 91.62% |
Volatility is currently contracting

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Medpace Holdings misrepresented or failed to disclose material information concerning the Company's backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio.

Medpace Holdings, Inc. (MEDP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

Medpace Holdings, Inc. MEDP regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MEDP and any ticker you trade — then tracks every position and per-strategy win rate.